Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
NNF Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
EMBO Mol Med. 2019 Nov 7;11(11):e10427. doi: 10.15252/emmm.201910427. Epub 2019 Sep 30.
Plasma and serum are rich sources of information regarding an individual's health state, and protein tests inform medical decision making. Despite major investments, few new biomarkers have reached the clinic. Mass spectrometry (MS)-based proteomics now allows highly specific and quantitative readout of the plasma proteome. Here, we employ Plasma Proteome Profiling to define quality marker panels to assess plasma samples and the likelihood that suggested biomarkers are instead artifacts related to sample handling and processing. We acquire deep reference proteomes of erythrocytes, platelets, plasma, and whole blood of 20 individuals (> 6,000 proteins), and compare serum and plasma proteomes. Based on spike-in experiments, we determine sample quality-associated proteins, many of which have been reported as biomarker candidates as revealed by a comprehensive literature survey. We provide sample preparation guidelines and an online resource ( www.plasmaproteomeprofiling.org) to assess overall sample-related bias in clinical studies and to prevent costly miss-assignment of biomarker candidates.
血浆和血清是个体健康状况信息的丰富来源,蛋白质检测可用于指导医学决策。尽管投入了大量资金,但很少有新的生物标志物能进入临床应用。基于质谱(MS)的蛋白质组学现在可以对血浆蛋白质组进行高度特异性和定量检测。在这里,我们采用血浆蛋白质组分析来定义质量标志物面板,以评估血浆样本,以及提示的生物标志物是否是与样本处理和处理相关的伪影。我们获取了 20 个人的红细胞、血小板、血浆和全血的深度参考蛋白质组 (>6000 种蛋白质),并比较了血清和血浆蛋白质组。基于添加实验,我们确定了与样本质量相关的蛋白质,其中许多已被报道为生物标志物候选物,这是通过全面的文献调查发现的。我们提供了样本制备指南和在线资源 (www.plasmaproteomeprofiling.org),以评估临床研究中与样本相关的总体偏差,并防止昂贵的生物标志物候选物错误分配。